# Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.

> **NCT00527488** · PHASE2 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 52 (actual)

## Conditions studied

- BPH

## Interventions

- **DRUG:** Degarelix
- **DRUG:** Degarelix
- **DRUG:** Degarelix
- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT00527488
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-03
- **Final completion:** 2009-05
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2015-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00527488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00527488, "Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00527488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*